Major Industry:
Drugs, Cosmetics & Health Care
Sub Industry:
Ethical Drug Manufacturers
Country:
United States
Currency:
U.S. Dollars
Fiscal Year Ends:
December
Employees
24 (oh gott, verdammt kleiner Laden ?)
Exchanges:
OTC
Share Type:
Market Capitalization:
112,521,345
Total Shares Outstanding:
303,292,035
Closely Held Shares:
91,653,133
Wright Quality Rating:
advanced Viral Research Corp. was incorporated to produce, market, promote and sell a pharmaceutical drug with the trade name "Reticulose". Reticulose is an anti-viral peptide-nucleic acid complex preparation used in the treatment of Asian Influenza, Viral Pneumonia, Virus Infectious Hepatitis, Mumps etc. The company's operations in the recent years have been
limited principally to engaging in research, in vitro testing and analysis of Reticulose on human patients overseas. The company has granted distribution rights for Reticulose in certain foreign countries.
The company is in the developmental stage, and has not yet commenced
commercial operations. It is dependent on registration and/or approval by applicable regulatory authorities of Reticulose, of which there can be no assurance.
Na, das ist zwar alles sehr positiv, aber hört sich verdammt riskant an.
Aber vielleicht sind das nicht die latest-news ?
CHECKIT
weiteres folgt, so ich es finde..
